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NSAIDs, Opioids, and Beyond
Coti Phillips, Edwin Contreras and Jessica Oswald
Abstract
Medications are prescribed throughout the world for a variety of reasons includ-
ing pain. NSAIDs, opioids, and other non-opioid modalities have been used to treat 
both acute and chronic pain. In this chapter we will discuss the pharmacokinetics, 
indications, function and associated complications for commonly used pain medi-
cations to include NSAIDs, opioids, antidepressants, cannabinoids, and ketamine.
Keywords: acute pain, chronic pain, NSAIDs, opioids, antidepressants, 
cannabinoids, ketamine
1. Introduction
Acute and chronic pain is a complex disease process that can be difficult to treat. 
Despite new developments in medications and technology, nonsteroidal anti-
inflammatory drugs (NSAIDs) and opioids are among the most widely prescribed 
medications in the world [1, 2]. In addition to NSAIDs and opioids, adjunctive 
pharmacologic agents to include antidepressants, cannabinoids and ketamine have 
increased in popularity. This chapter aims to review commonly prescribed pain 
medications with a focus on their classification categories, mechanisms of action, 
and major side effect profiles.
2. NSAIDs
Nonsteroidal anti-inflammatory drugs (NSAIDs) were first introduced in the 
1960s and are the most prescribed medication class in the world. The United States 
issues more than 100 million prescriptions annually [3] with approximately 20% 
of its citizens using NSAIDs on a frequent monthly basis at some point during their 
lifetime [4].
NSAIDs are a diverse group of compounds with varying chemical structures that 
possess anti-inflammatory, antipyretic, and analgesic properties [5]. They represent 
a class of drugs with a primary mechanism of action that involves inhibition of 
the pro-inflammatory cyclooxygenase (COX) enzymes. This includes both non-
selective COX inhibitors (COX-1 and COX-2) including aspirin, indomethacin, and 
ibuprofen as well as the newer selective COX-2 inhibitors such as celecoxib. NSAIDs 
have an established short-term efficacy in the treatment of osteoarthritis (OA) and 
associated chronic low back pain as well as an opioid sparing effect when combined 
with most chronic pain management regimens [6, 7]. Despite the well-documented 
efficacy of NSAIDs, there are serious side effects associated with routine use that 
include gastrointestinal irritation (gastritis and ulceration of the stomach and small 
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intestine), cardiovascular events (myocardial infarction, hypertension exacerba-
tion) and renal toxicity (acute renal failure, electrolyte and fluid abnormalities).
2.1 Mechanism of action
Prostaglandins are lipid compounds that are physiologically active and have 
a diverse range of homeostatic and inflammatory effects in the human body that 
modulate fever and pain. They are the primary mediators of inflammatory cascades 
resulting in peripheral sensitization, hyperalgesia and chronic pain. Prostaglandin 
H2 (PGH2) is a common precursor for prostaglandins (PGE2, PGI2, and PGF2) and 
thromboxane. It is synthesized from arachidonic acid via the rate limiting enzyme 
cyclooxygenase (COX) (Figure 1). By inhibiting the cyclooxygenase (COX) 
enzymes and thus inhibiting prostaglandin synthesis, NSAIDs are able to produce 
their analgesic and anti-inflammatory effects. COX exists in two isoforms, COX-1 
and COX-2. COX-1 is expressed throughout the body and is a normal component of 
most cells. It is a necessary in the production of protective gastric mucosal secre-
tions and regulation of gastric acid, promotion of platelet aggregation and the 
maintenance of renal blood flow [8]. COX-2, however, is minimally expressed and 
tightly regulated under normal conditions but is induced with the pro-inflamma-
tory stimuli seen with cellular injury (IL-1, TNF-alpha tumor necrosis factor–alpha, 
and cytokines) [9]. Given some of the beneficial aspects of COX-1 and the specific 
pro-inflammatory aspect of COX-2, newer NSAIDs are directly targeted at selective 
Figure 1. 
Production and actions of prostaglandins and thromboxane (adapted from [52]).
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inhibition of COX-2 and are collectively referred to as coxibs. NSAIDs are other-
wise non-selective in their inhibition of COX-1 and COX-2 although with varying 
 affinity (Table 1).
2.2 Side effects
The same mechanism of action that provides the therapeutic effect of NSAIDs 
is also most commonly responsible for the side effects associated with chronic use. 
By inhibiting prostaglandin synthesis, NSAIDs increase the risk of gastrointestinal 
bleeding [10–14], thrombosis [15], and myocardial infarction [16]. COX-1 medi-
ated synthesis of PGE2 is responsible for gastric mucosa integrity. Inhibiting PGE2 
NSAID COX-2 
selectivity•
Gastrointestinal 
risk
Cardiovascular 
risk
Clinical use
Aspirin Low Moderate Low Prevention of 
cardiovascular events, 
mild pain, and 
inflammation
Ibuprofen Moderate Low Moderate to high Osteoarthritis, 
rheumatoid arthritis, 
fever, dysmenorrhea, 
mild to moderate pain, 
headache, migraine, 
myalgia
Diclofenac High Moderate High Osteoarthritis, 
rheumatoid arthritis, 
fever, dysmenorrhea, 
mild to moderate pain, 
migraine
Indomethacin Low Moderate to high Moderate to high Osteoarthritis, 
rheumatoid arthritis, 
bursitis, tendinitis, 
mild to moderate pain, 
or severe pain
Naproxen Low Moderate to high Low Gouty arthritis, mild 
to moderate pain, 
tendonitis, fever, 
rheumatoid disorders, 
osteoarthritis, 
dysmenorrhea, 
migraine prevention
Meloxicam High Low Moderate to high Osteoarthritis, 
rheumatoid arthritis
Celecoxib High Low Moderate to high Osteoarthritis, 
ankylosing spondylitis, 
rheumatoid 
arthritis, acute pain, 
dysmenorrhea
Adapted from [53].
*Only generic names provided. List not all inclusive. Keep in mind NSAIDs carry varying risks of rare liver toxicity 
and renal failure.
•Selectivity is based on in vitro assay studies and should be interpreted with caution as different assay methods give 
different results. No assay method can predict what will happen when the drug is given to patients. Clinical studies 
are the best way to determine the effects of NSAIDs in patients.
Table 1. 
Safety comparison of some of the most commonly used NSAIDs.*
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production with traditional non-selective NSAIDs results in gastric mucosal impair-
ment and injury. Gastroduodenal ulcers are commonly identified with endoscopy 
after chronic non-selective NSAID use with double-blind trials showing incidence 
as high as 46% after 24 weeks of ibuprofen use [17]. Extra care must be taken with 
NSAID use in special populations including the elderly and those with underlying 
gastric irritation, stress related gastric mucosal injury (SRMD), and portal hyper-
tensive gastropathy.
Given the side effects associated with inhibition of COX-1, especially the 
GI toxicity noted above, selective COX-2 inhibiting NSAIDs were created with 
the intention of avoiding harmful GI events while continuing to retain the anti-
inflammatory and analgesic benefits of COX-2 antagonism. The selective COX-2 
inhibition that occurs with coxibs (celecoxib, rofecoxib) was, however, believed to 
be associated with increased cardiovascular (CV) events including hypertension 
and thrombosis. The CV side effects are attributed to the imbalance in vascular 
tone and clotting hemostasis that is in part regulated by arachidonic metabolites; 
with COX-1 mediated TXA2 being an inducer of platelet aggregation and COX-2 
mediated PGI2 being an inhibitor of platelet aggregation [18]. This is highlighted 
with PGI2 receptor deficient mice being more prone to thrombosis then wild type 
mice [19]. Ultimately, large randomized controlled trials showed that celecoxib in 
moderate doses was non-inferior to naproxen or ibuprofen (non-selective NSAIDs) 
in regards to a primary outcome of cardiovascular causes of death [20].
3. Opioids
Opioids have been used for the management of pain since the earliest records 
of human history. The Sumerians of Mesopotamia were the first to cultivate the 
poppy plant [21]. Further refinement paralleled the advancement of human 
growth with the first extraction of morphine from opium occurring in 1803 
[22]. New formulations, concentrations, and routes of delivery were developed 
and there was a simultaneous increase in medicinal as well as recreational use. 
Opiate use peaked between 1999 and 2017 and was responsible for approximately 
400,000 overdose related deaths [23]. This has culminated into the current state 
of affairs where narcotic prescription abuse has become a national crisis with 
strict regulations on prescribing now in place. The fine balance between proper 
medical uses for the treatment of acute and chronic pain versus inappropriate 
overprescribing is being heavily scrutinized requiring careful consideration of 
the appropriateness of initiating opioids and the risks and benefits of chronic 
use. The importance of this is demonstrated with meta-analysis showing roughly 
5% of patients prescribed an opioid for pain developing iatrogenic opioid depen-
dence or abuse [24]. One must have an intimate understanding of the various 
opioid medications available and take a careful and strategized approach to 
prescribing a chronic regimen to suitably navigate this dilemma. Nonetheless, 
opioids remain a mainstay in the treatment of acute and chronic cancer related 
pain. This is in contrast to the benefit of opioids used in chronic non-malignant 
pain with studies continuing to show little to no benefit in quality of life or 
functional capacity [25, 26].
3.1 Mechanism of action
The classification of opioid commonly refers to all compounds that bind to the 
opiate receptors. This includes the naturally occurring alkaloids derived from the 
opium poppy (morphine, codeine), semi-synthetic opioids which are synthesized 
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from naturally occurring opiates (oxycodone, heroin) and fully synthetic opioids 
(methadone, fentanyl). Opioids as a class are similar in that they all cause analgesia 
and have a common side effect profile. Opioid drugs impart their effects primar-
ily through three receptors: Mu (μ), Delta (δ), and Kappa (κ) (Table 2). These 
receptors are found both peripherally and centrally and can be activated all along 
the neuroaxis including the cortex, brainstem, interneurons of the spinal cord and 
the nociceptors at the level of the primary sensory neurons. Activation of these 
receptors is responsible for both the analgesic properties of opioids as well as the 
major side effects. All opioid receptors are G-protein coupled receptors that inhibit 
adenylyl cyclase, decreasing conductance of voltage-gated Ca++ channels and/or 
opening rectifying K+ channels (Figure 2). This ultimately prevents calcium influx 
and the release of pronociceptive neurotransmitters (glutamate, substance P, and 
calcitonin gene-related peptide from the nociceptive fibers) [27]. By preventing the 
release of these pain-promoting neurotransmitters, opioids are able to impart their 
analgesic properties.
3.2 Opioid receptors
Mu receptors are largely thought of as the primary receptor responsible for 
analgesia with opioids; thus, the term “mu agonist” is often used to describe opioids 
used for the management of pain. Mu opioid receptors (MOR) are found in high 
density at the periaqueductal gray (PAG) of the midbrain. Agonism of MOR in this 
region is thought to eliminate a tonic gamma aminobutyric acid (GABA) tone thus 
Mu (μ) Delta (δ) Kappa (κ)
Mu 1: Analgesia
Mu 2: Sedation, vomiting, 
respiratory depression, 
pruritus, euphoria, 
anorexia, urinary retention, 
physical dependence
Analgesia, 
spinal 
analgesia
Analgesia, sedation, dyspnea, 
psychomimetic effects, miosis, 
respiratory depression, euphoria, 
dysphoria, dyspnea
Endogenous peptides
Enkephalins Agonist Agonist
Beta-endorphin Agonist Agonist
Dynorphin A Agonist Agonist
Agonists
Morphine Agonist Weak agonist
Codeine Weak agonist Weak agonist
Fentanyl Agonist
Meperidine Agonist Agonist
Methadone Agonist
Antagonists
Naloxone Antagonist Weak 
antagonist
Antagonist
Naltrexone Antagonist Weak 
antagonist
Antagonist
Adapted from [29, 54].
Table 2. 
Analgesic effects at opioid receptors.
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indirectly stimulating descending inhibitory pathways at the level of the spinal cord 
[28]. MOR receptors are also in high density on dorsal horn neurons and elicit their 
analgesic effect through inhibition of glutamine release decreasing the transmission 
of nociceptive information from A-delta and C nerve fibers.
The drugs that are able to fully activate these mu receptors in a dose depen-
dent fashion are referred to as full agonists. This is in contrast to the drugs that 
are either weak agonists at the mu receptor (while preventing other full agonists 
from binding) or are antagonists at the mu receptor while being an agonist at 
another receptor. These are referred to as agonist-antagonist drugs and include 
buprenorphine+naloxone (suboxone), nalbuphine, and pentazocine. Reversal of 
the effects caused by mu agonists is accomplished with competing antagonists 
(naloxone), which are crucial in the medical management of opioid overdoses 
and the associated respiratory depression. Kappa and delta receptors also con-
tribute to analgesia and the other clinical effects seen with acute and chronic use 
including respiratory depression and sedation. Kappa receptors, in particular, 
are localized in the brain stem and spinal cord and are chiefly responsible for 
providing spinal analgesia [29]. Opioid receptors also bind to endogenous opioid 
Figure 2. 
Mechanisms of opioid action in the spinal cord.
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peptides (endorphins, enkephalins, and dynorphins), which are important in 
overall pain modulation.
The clinical use of opioids is dependent upon more than just the receptor 
specificity and relies on deep understanding of the pharmacokinetics of these drugs 
for optimal use. In a basic sense, opioids can be classified into either short or long 
acting agents although this terminology inappropriately simplifies complex phar-
macodynamic and pharmacokinetic properties of these drugs.
3.3 Side effects
The interaction between exogenous opioids and opioid receptor activation has 
a diverse side effect profile with variable differences seen with acute and chronic 
use. These side effects include constipation, nausea and vomiting, hyperalgesia, 
opioid induced hormonal changes, and respiratory depression. Opioid induced 
constipation (OIC) is one of the most commonly seen side effects with roughly 
one half of patients experiencing OIC with long-term use [30]. OIC can cause 
significant morbidity with associated adverse effects including fecal impaction 
with obstruction, reflux, dyspepsia, cramping/pain, and lengthened hospitaliza-
tion [31]. For this reason, all chronic opioid regimens should include prophylactic 
laxatives. Mu opioid receptors are abundant in the respiratory rhythm generating 
regions of the brainstem and pons. Agonism of these receptors causes opioid 
induced breathing alterations including significant reduction in respiratory rate 
and minute ventilation with associated hypercapnia. This can ultimately lead to 
fatal apnea, especially with lipophilic opioids and intravenous administration 
that allows for quick equilibration at the effect compartment (central respiratory 
centers) [32]. Given the euphoria that occurs with opioids, addiction is another 
potential iatrogenic side effect seen with acute and chronic use. This can be 
associated with tolerance to opioids, which is defined as a decreased objective 
and subjective effect with a stable dose over time as well as requiring increasing 
amount of an opioid to achieve the same effect. Increasing tolerance also devel-
ops to the other effects of opioids including respiratory depression [22]. This is 
problematic in patients abusing opioids given the tendency for relapse back to a 
previous dose that will now cause profound respiratory depression due to the loss 
of tolerance during abstinence.
4. Antidepressants
Antidepressants have a long established efficacy in the treatment of neu-
ropathic predominant chronic pain disorders [33]. Neuropathic pain disorders 
develop from a multitude of disease processes that directly arise from lesions or 
other damage to the central or peripheral somatosensory nervous system [34]. 
Associated diseases and processes include diabetes mellitus (diabetic peripheral 
neuropathy), HIV (HIV polyneuropathy), herpes zoster (post-herpetic neuralgia), 
and medical interventions (e.g., post-mastectomy pain, chemotherapy). Tricyclic 
antidepressants (TCAs) including amitriptyline, imipramine, and nortriptyline 
are routinely used as first line options in the management of neuropathic pain 
[33, 35]. TCAs can be started and maintained at doses lower than the doses used 
in depression thus reducing some of the side effects commonly seen at depression 
doses such as dry mouth, sedation, urinary retention and orthostatic hypoten-
sion. TCAs must be used cautiously in patients taking other serotonergic drugs 
or in patients with a history of cardiovascular disorders, glaucoma, or urinary 
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retention given the anticholinergic side effects TCAs can produce. Of note, TCAs 
are beneficial to both depressed and non-depressed patients as well as having 
the added value of helping with depression in the depressed subpopulation [33]. 
Serotonin-norepinephrine reuptake inhibitors (SNRIs) are also commonly used 
in the management of chronic pain with duloxetine having FDA approval for the 
management of fibromyalgia and venlafaxine showing superiority to placebo in 
the treatment of diabetic neuropathy [36, 37].
The primary mechanism of action of TCAs in the treatment of neuropathic pain 
involves the reuptake inhibition of norepinephrine (NE) and serotonin (5-hydroxy-
tryptamine [5-HT]), which causes a blockade of the neuronal membrane ion chan-
nels and increases the activation of descending inhibitory pathways in the midbrain 
and spinal cord [38, 39]. SNRIs also elicit their effect through inhibition of NE and 
5-HT blocking their role in descending pain pathways.
5. Cannabinoids
The term cannabinoid is used to collectively describe all naturally occurring 
and synthetic compounds that are structurally similar to and elicit similar effects 
as the cannabinoid plants, most notably cannabis. In addition to the cannabi-
noids derived from plants (phytocannabinoids), there are also endogenously 
produced cannabinoids (endocannabinoids) and synthetic cannabinoids now 
being produced for medical use. Endocannabinoids are fundamental in human 
homeostasis with established behavioral, metabolic, immunologic, and physi-
ologic functions [40]. Cannabinoids bind to two isotypes of G protein coupled 
receptors, CB1 and CB2 [41]. The CB1 receptor is found predominantly in the 
CNS including the brain, spinal cord, and the sensory nerve terminals and along 
primary pain pathways. Activation of CB1 receptors at these sites results in mem-
brane hyperpolarization and the modulation of nociceptive neurotransmitters 
contributing to both the pain relief and psychotomimetic properties of can-
nabinoids [42]. This reduced pain with cannabinoid receptor agonists can occur 
at multiple levels of the CNS both peripherally and centrally. CB2 receptors are 
concentrated in the hematopoietic cells of the immune system and are involved 
in a diverse range of immunomodulatory effects including the inhibition of 
cytokine release [43, 44].
Cannabis contains over 500 chemical compounds including over 150 phytocan-
nabinoids with the most studied being Δ9-tetrahydrocannabinol (THC) and can-
nabidiol (CBD). THC is the chief psychotropic compound of cannabis and is found 
in varying concentrations in different strains of the plant. THC has a strong affinity 
for CB1, which is regarded as the primary receptor responsible for the psychoactive 
effects seen with cannabis. In contrast, CBD does not activate CB1 so it does not pro-
duce psychoactive effects and is associated more with the anti-inflammatory effects 
of cannabinoids [45]. There are currently three cannabinoid drugs available for use 
in the United States. Epidolex® is a CBD based drug used to treat epileptic disor-
ders and is derived from cannabis. Dronabinol and Nabilone are synthetic THC 
compounds approved for use in chemotherapy associated nausea and as an appetite 
stimulant in HIV/AIDS [46]. Molecular and preclinical evidence continues to sup-
port the anti-nociceptive properties of cannabinoids although experimental human 
studies are more heterogeneous with varying results although ongoing research is 
being conducted [47]. With major legislative changes in the USA, thirty-three states 
and the District of Columbia have passed laws broadly legalizing cannabis in some 
form at the time of this writing.
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6. Ketamine
Ketamine is a dissociative analgesic and amnestic medication that acts as a 
non-competitive antagonist of the N-Methyl-D-Aspartate (NMDA) receptor in 
the central nervous system [48]. It has been used since the 1960s as an anesthetic 
agent and continues to be studied and adapted for novel psychiatric and anesthetic 
purposes. Ketamine has multiple sites of drug action but its principal nociceptive 
effects occur at the NMDA receptors. NMDA receptors have dense expression in the 
temporal cortex, hippocampus, basal ganglia, cerebellum and brain stem and are 
known to contribute to the neuronal process that mediate nociception via activation 
by glutamate, an excitatory amino acid [49]. By targeting this receptor, ketamine 
has profound attenuating effects on ascending nociceptive transmission and ampli-
fication of descending inhibitory pathways [49, 50]. Ketamine is currently utilized 
in the management of many diseases and other applications including the manage-
ment of chronic pain disorders (e.g., complex regional pain syndrome, phantom 
limb pain, fibromyalgia), acute pain, conscious sedation, and intraoperatively for 
antihyperalgesia and induction of anesthesia [51].
7. Conclusions
NSAIDs have been used historically to treat both acute and chronic pain. They 
possess analgesic, antipyretic, and anti-inflammatory properties through the 
inhibition of the pro-inflammatory cyclooxygenase (COX) enzymes. Their mecha-
nism of action allows them to establish efficacy in treating a variety of pain diseases 
but also allows their routine use to produce serious side effects. COX-1 receptors are 
expressed throughout our body and its inhibition can lead to gastric mucosal injury 
including gastroduodenal ulcers. Selective COX-2 inhibitors were created with 
hopes of avoiding the side effects connected with non-selective COX-inhibitors; 
however, they are associated with their own complications which include an 
increased risk for cardiovascular events (thrombosis and hypertension).
Opioids remain a popular option in treating pain due to their effect on the Mu 
(μ), Delta (δ), and Kappa (κ) receptors. By activating these receptors, opioids can 
prevent the release of pain-promoting neurotransmitters providing their analgesic 
effects. However, the activation of the same receptors is also responsible for the 
associated side effects. These side effects vary depending on either acute or chronic 
use but can be life-threatening in some cases. This includes respiratory depression 
which can lead to fatal apnea. Chronic opioid use is associated with opioid induced 
constipation that can cause significant morbidity. It is therefore recommended to 
include prophylactic laxatives with chronic regimens. It is important to remember 
that addiction and tolerance is associated with opioid use due to its euphoric effect. 
Therefore, the clinical use of these medications should not only depend on their 
mechanism of action but also on understanding the potential severe complications 
that arise with their use.
Neuropathic chronic pain disorders have been effectively treated with anti-
depressants. These disorders include, but are not limited to, diabetic peripheral 
neuropathy, HIV polyneuropathy, and post-herpetic neuralgia. One of the first 
line options are the tricyclic antidepressants (TCAs) which are usually started and 
maintained at lower doses versus the depression doses. This helps reduce some 
of their side effects including urinary retention, sedation, and dry mouth. Other 
antidepressants include serotonin-norepinephrine reuptake inhibitors that are also 
used in the management of neuropathic disorders.
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Cannabinoids exhibit their effects by binding to CB1 and CB2 receptors, two iso-
types of G-protein coupled receptors. The agonism of these receptors is responsible 
for cannabinoids’ anti-inflammatory and analgesic effects. CB1 receptor agonism 
is also predominately responsible for the psychoactive effect. Preclinical evidence 
supports anti-nociceptive effects and with recent legalization of cannabis, the use 
of cannabinoids to treat pain disorders will expand with ongoing research.
Ketamine has many uses in treating both acute and chronic pain including 
fibromyalgia. It is also used for conscious sedation due to both its dissociative and 
amnestic properties. Ketamine has multiple sites of interactions but it exhibits 
its principle nociceptive effect by acting as a non-competitive antagonist of the 
N-Methyl-D-Aspartate (NDMA) receptor.
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